查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924744

沙庫巴曲Valsartan鈉製劑市場按類型、規格、最終用戶和分銷管道分類－2026年至2032年全球預測

Sacubitril Valsartan Sodium Drugs Market by Type, Strength, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，沙庫巴曲Valsartan鈉製劑市場價值將達到 105.8 億美元，到 2026 年將成長至 113.7 億美元，到 2032 年將達到 178.5 億美元，複合年成長率為 7.75%。

主要市場統計數據
基準年 2025 105.8億美元
預計年份：2026年 113.7億美元
預測年份：2032年 178.5億美元
複合年成長率 (%) 7.75%

這是一份簡明扼要的基礎性概述，重點介紹了影響產業相關人員策略決策的臨床、監管和商業性因素。

沙庫巴曲Valsartan鈉是治療心臟衰竭的關鍵藥物，臨床、商業和監管領域的相關人員正在積極應對不斷變化的證據、製劑策略和市場准入管道。本執行摘要總結了影響治療、分銷和政策環境的關鍵趨勢，旨在幫助決策者根據觀察到的變化調整臨床開發、產品生命週期和市場進入政策。

臨床證據的趨同、監管壓力的增加、支付方的要求以及分銷管道的演變，正在重塑產品策略和競爭定位。

近年來，多種因素共同重塑了沙庫巴曲Valsartan鈉市場，包括真實世界證據的增加、監管機構對治療等效性的日益重視、採購重點的轉變以及配銷通路的快速成熟。這些因素促使生產者增加對改良製劑、加強藥物監測和病患支持計畫的投入，以提高門診和住院病患的用藥遵從性。

2025 年政策主導的關稅和貿易調整正在加速整個醫藥價值鏈的供應鏈多元化、合約重組和緊急時應對計畫計畫。

2025年的關稅和貿易干預措施凸顯了建構具有韌性的藥品供應鏈和多元化籌資策略的重要性。隨著關稅措施改變原料成本和跨境生產的經濟效益，製造商和經銷商正在透過重新評估其供應基礎、尋找替代製造地和建立緩衝庫存來應對，以確保基本治療藥物的持續供應。

按類型、強度、最終用戶和分銷管道進行細分，以協調產品系列中的臨床支援、供應保障和商業化策略。

以細分市場為導向的產品策略方法能夠識別出臨床和商業性干預措施影響最大的領域。類型分析區分品牌藥和學名藥，每類藥品都需要不同的支援架構。品牌藥受益於以結果為導向的證據生成和患者支持服務，而學名藥需要最佳化成本結構、快速擴大生產規模以及強力的分銷協議，以確保競標和藥房上架機會。

全球各區域的監管差異、採購結構和數位化應用模式如何塑造差異化的市場進入和商業化方式？

區域趨勢對監管方式、分銷模式和相關人員的期望有著深遠的影響。在美洲，監管管道正圍繞著明確的生物等效性和互換性標準進行整合，大規模綜合醫療系統正在推動集中採購和基本契約。因此，製造商優先考慮文件的清晰度、支付方證據支持以及供應的可靠性，以滿足監管機構的要求。

競爭優勢取決於臨床差異化、多樣化的生產能力以及能夠提供可追溯性和跨所有分銷管道快速補貨的分銷合作夥伴。

沙庫巴曲Valsartan鈉市場的競爭格局主要受臨床差異化、生產能力和上市速度的影響。領先的創新企業正著重於生命週期策略，例如擴大強大的臨床項目、加強患者支援服務、開發新型製劑以及採用聯合包裝等，以鞏固其臨床優勢。同時，非專利製劑生產商則優先考慮提高規模化生產效率、完善生物等效性監管文件以及與經銷商建立戰略合作夥伴關係，以確保處方箋目錄並贏得競標。

切實可行的策略性舉措，旨在提升臨床應用率、增強供應韌性、最佳化管道並加強與支付方的合作，從而確保永續的競爭優勢。

產業領導者應採取一系列切實可行的措施，以確保臨床應用、供應穩定性和支付方參與。首先，透過將真實世界證據的生成納入產品生命週期，並記錄日常臨床實踐中的療效對比和依從性獲益，加強與支付者和醫院處方集委員會的對話。其次，透過對二級原料藥和成品藥供應商進行資格認證，並協商能夠應對貿易相關成本波動和物流中斷的靈活合約條款，實現供應鏈多元化。

一個融合多種研究方法的調查方法框架，旨在提供可操作的見解：結合關鍵相關人員訪談、監管分析、臨床證據綜合和供應鏈審核。

本報告採用混合方法，整合了定性和定量資訊，包括對關鍵相關人員的訪談、監管文件審查、臨床文獻綜述和供應鏈審核。報告對臨床醫生、醫院藥劑師、採購專業人員和商業部門負責人進行了初步訪談，以了解他們對劑量偏好、採購週期和分銷管道要求的觀點。監管和政策分析則參考了已發布的指南、核准摘要和支付方框架，以確保與現行法規和報銷實踐保持一致。

這份簡明扼要的綜述重點闡述了臨床可靠性、營運韌性和支付方合作這三者之間相互關聯的優先事項，而這些事項對於持續的醫療服務取得和推廣至關重要。

總體而言，沙庫巴曲Valsartan鈉仍然是治療心臟衰竭的核心藥物，但由於證據的不斷積累、法規的演變、配銷通路的創新以及政策主導的供應挑戰，其商業和運營環境正在迅速變化。整合臨床證據策略、擁有多元化製造地和針對特定管道的商業模式的機構，將更有利於在複雜的採購環境中維持藥物供應並保持價值。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章 美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

8. 沙庫巴曲Valsartan鈉製劑市場（按類型分類）

  • 品牌
  • 非專利的

9. 沙庫巴曲Valsartan鈉製劑市場（依濃度分類）

  • 24～26mg
  • 49～51mg
  • 97～103 mg

第10章 沙庫巴曲Valsartan鈉製劑市場（依最終用戶分類）

  • 診所
  • 居家醫療
  • 醫院

第11章 沙庫巴曲Valsartan鈉製劑市場（依通路分類）

  • 離線
  • 線上

第12章 沙庫巴曲Valsartan鈉製劑市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 沙庫巴曲Valsartan鈉製劑市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國沙庫巴曲Valsartan鈉製劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國沙庫巴曲Valsartan鈉製劑市場

第17章：中國沙庫巴曲Valsartan鈉製劑市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Aspen Pharmacare Holdings Limited
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Hetero Labs Limited
  • Lupin Limited
  • MacLeod's Pharmaceuticals Ltd.
  • MSN Laboratories Private Limited
  • Mylan NV
  • Natco Pharma Limited
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Lifesciences Limited
Product Code: MRR-7A380DA7C46F

The Sacubitril Valsartan Sodium Drugs Market was valued at USD 10.58 billion in 2025 and is projected to grow to USD 11.37 billion in 2026, with a CAGR of 7.75%, reaching USD 17.85 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.58 billion
Estimated Year [2026] USD 11.37 billion
Forecast Year [2032] USD 17.85 billion
CAGR (%) 7.75%

A concise foundational overview clarifying clinical, regulatory, and commercial vectors that shape strategic decision-making for industry stakeholders

Sacubitril valsartan sodium represents a cornerstone therapy class in heart failure management, and stakeholders across clinical, commercial, and regulatory domains are navigating evolving evidence, formulation strategies, and access pathways. This executive summary synthesizes key dynamics shaping the therapeutic, distributional, and policy environment so that decision-makers can align clinical development, product lifecycle, and market access actions with observed shifts.

The drug's clinical profile, combined with ongoing guideline updates and payer dialogues, continues to influence prescribing patterns and procurement strategies. As clinical use diversifies across settings and dosing regimens, manufacturers and distributors are adapting product positioning, labeling, and support services in response. Regulators are also clarifying interchangeability, bioequivalence requirements, and real-world evidence expectations, which together affect approval timelines and post-market commitments.

Consequently, commercial stakeholders must balance clinical evidence translation with supply reliability, pricing pressures, and channel optimization. This overview provides an integrated perspective across therapeutic, policy, and distribution vectors to inform strategic choices without presuming numerical projections, focusing instead on the qualitative implications for operations, partnerships, and clinical engagement.

How converging clinical evidence, regulatory rigor, payer demands, and channel evolution are realigning product strategies and competitive positioning

In recent years the landscape around sacubitril valsartan sodium has been reshaped by several converging forces: stronger real-world evidence generation, regulatory emphasis on therapeutic equivalence, shifts in procurement priorities, and the rapid maturation of distribution channels. These forces have prompted manufacturers to refine formulations, strengthen pharmacovigilance, and invest in patient-support programs that improve adherence across ambulatory and inpatient settings.

Concurrently, payers and health systems have increased demands for cost-effectiveness demonstration and outcomes-based contracting, prompting sponsors to develop more granular value dossiers and real-world evidence plans. Advances in generic formulation technology and regulatory pathways have also accelerated competition, leading to intensified focus on differentiation through patient services, branded-combination strategies, and extended-release or alternative-dosage presentations.

Distribution has transformed as well: hospital procurement teams, retail pharmacies, and online dispensaries each require tailored supply-chain guarantees, data reporting, and commercial terms. Together, these shifts demand that organizations adopt integrated strategies spanning clinical evidence generation, product lifecycle management, payer engagement, and channel-specific operations to maintain clinical adoption and contractual advantage.

Policy-driven tariffs and trade adjustments in 2025 have accelerated supply chain diversification, contract reengineering, and contingency planning across the pharmaceutical value chain

Policy interventions on tariffs and trade in 2025 have underscored the importance of resilient pharmaceutical supply chains and diversified sourcing strategies. When tariff measures alter input costs or the economics of cross-border manufacture, manufacturers and distributors respond by reassessing supplier bases, qualifying alternate manufacturing sites, and increasing buffer inventories to preserve continuity of supply for essential therapies.

In practice, firms have accelerated supplier qualification for secondary active pharmaceutical ingredient sources and expanded contract manufacturing agreements in multiple jurisdictions to mitigate exposure to single-country tariff shifts. Parallel strategies include nearshoring select manufacturing steps, renegotiating long-term supply contracts with price adjustment clauses, and investing in supply-chain visibility tools to track cost drivers in real time. These actions reduce tariff sensitivity and support negotiations with payers and procurement entities that demand predictable pricing and uninterrupted availability.

Procurement teams and hospital pharmacies have tightened contractual language around force majeure, customs delays, and import duties. Meanwhile, commercial teams are preparing multilayered pricing scenarios and communication plans to maintain prescriber confidence and avoid abrupt formulary disruptions. Ultimately, the cumulative policy environment has reinforced the need for scenario-based planning, diversified production footprints, and proactive stakeholder communication to sustain access and manage cost pressures without compromising quality or clinical supply.

Applying type, strength, end-user, and distribution channel segmentation to align clinical support, supply assurance, and commercialization tactics for product portfolios

A segmentation-aware approach to product strategy clarifies where clinical and commercial interventions will have greatest impact. Analysis by Type distinguishes between Brand and Generic formulations, and each category demands distinct support frameworks: branded products benefit from outcomes-focused evidence generation and patient-support services, while generics require optimized cost structures, rapid manufacturing scale-up, and strong distribution agreements to secure tender and pharmacy placement.

Strength segmentation across 24-26 mg, 49-51 mg, and 97-103 mg dosages highlights the importance of portfolio breadth and dosing convenience in clinical practice. Clinicians prioritize dose flexibility and clarity in titration pathways, so product teams must align labeling, packaging, and educational materials to reduce dosing errors and improve adherence across these strength bands. End-user segmentation into Clinics, Home Care, and Hospitals reveals divergent purchasing cycles and service expectations; clinics and home-care providers often demand reliable dispense programs and patient-support integration, whereas hospitals emphasize bulk procurement efficiencies and inpatient adherence protocols.

Distribution channel segmentation-Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy-further refines commercial tactics. Hospital pharmacies need transparent cold-chain and batch-traceability assurances, online pharmacies require robust digital patient engagement and adherence tools, and retail pharmacies prioritize point-of-sale availability, reimbursement navigation, and OTC complement strategies. Integrating insights across these segmentation lenses enables targeted commercialization, supply planning, and clinical support activities without relying on numerical projections.

How regional regulatory variety, procurement architectures, and digital adoption patterns are shaping differentiated market entry and commercialization approaches across global regions

Regional dynamics exert a powerful influence on regulatory approaches, distribution models, and stakeholder expectations. In the Americas, regulatory pathways have coalesced around explicit bioequivalence and interchangeability criteria, while larger integrated health systems drive centralized procurement and outcomes-based contracting; manufacturers therefore prioritize dossier clarity, payer evidence packages, and supply reliability to meet institutional requirements.

Europe, the Middle East & Africa present a mosaic of regulatory frameworks and reimbursement paradigms that require adaptive market entry strategies. Several countries in Europe are emphasizing real-world evidence and health-technology assessment alignment, while Middle Eastern and African markets often combine centralized procurement with capacity-building initiatives; this diversity requires flexible pricing strategies, tiered service offerings, and local partner selection that can manage registration and distribution complexities.

Asia-Pacific exhibits rapid adoption of digital pharmacy models alongside continued importance of hospital-driven procurement in major markets. Regulatory modernization efforts across the region are shortening review timelines for well-documented submissions, but local manufacturing requirements and variable reimbursement systems necessitate hybrid approaches that combine regional manufacturing partnerships, digital patient support, and tailored health economic communications. Across all regions, supply-chain resilience, regulatory engagement, and payer dialogue remain central to successful market operations.

Competitive positioning hinges on clinical differentiation, diversified manufacturing, and distribution partners that deliver traceability and rapid replenishment across channels

Competitive dynamics in the sacubitril valsartan sodium landscape are driven by clinical differentiation, manufacturing capacity, and go-to-market agility. Leading innovators emphasize robust clinical-program extensions, enhanced patient-support services, and lifecycle tactics such as novel formulations or co-packaging to protect clinical positioning. At the same time, manufacturers of nonproprietary formulations prioritize efficiency in scale-up, regulatory dossier completeness for bioequivalence, and strategic partnerships with distributors to secure formulary and tender wins.

Across the value chain, contract manufacturing organizations and API producers play a decisive role in supply stability; firms with diversified manufacturing footprints and multi-country qualifications for active pharmaceutical ingredients are better positioned to manage regulatory inspections and regional demand fluctuations. Distribution partners that combine national hospital access with growing digital pharmacy capabilities offer attractive channels for both branded and generic suppliers, and those who can provide cold-chain assurance, lot-level traceability, and rapid replenishment services gain a competitive edge.

Finally, successful companies are investing in clinician engagement and post-market evidence collection to sustain clinical trust. Real-world outcomes programs that demonstrate adherence benefits, reduced readmissions, or simplified titration can materially influence procurement committees and prescribers, reinforcing the need for clinical affairs functions to work closely with commercial teams to translate evidence into contract language and clinical protocols.

Practical strategic moves to strengthen clinical adoption, supply resilience, channel optimization, and payer alignment for sustained competitive advantage

Industry leaders should adopt a set of actionable moves to secure clinical adoption, supply resilience, and payer alignment. First, embed real-world evidence generation into product lifecycles to document comparative outcomes and adherence benefits in routine care, enabling stronger dialogues with payers and hospital formulary committees. Second, diversify supply chains by qualifying secondary API and finished-dose suppliers, and by negotiating flexible contract terms that account for trade-related cost variability and logistical disruptions.

Third, design channel-specific commercial programs: create hospital-facing value bundles that address procurement cycles and bulk replenishment, build digital adherence platforms for online pharmacy partners, and support retail pharmacy placement with point-of-care educational material. Fourth, align regulatory and clinical affairs teams to pursue streamlined interchangeability and bioequivalence dossiers while proactively preparing post-market surveillance plans to ensure compliance and prescriber confidence.

Finally, prioritize collaborative contracting mechanisms with payers-such as outcome-linked agreements or risk-sharing constructs where appropriate-that demonstrate commitment to value while preserving access. Taken together, these steps create a resilient, evidence-based approach that supports long-term clinical adoption and operational continuity.

A mixed-methods research framework combining primary stakeholder interviews, regulatory analysis, clinical evidence synthesis, and supply-chain audits to underpin actionable insights

This report synthesizes qualitative and quantitative inputs using a mixed-methods approach that integrates primary stakeholder interviews, regulatory document review, clinical literature synthesis, and supply-chain audits. Primary interviews were conducted with clinicians, hospital pharmacists, procurement specialists, and commercial leaders to capture on-the-ground perspectives related to dosing preferences, procurement cycles, and channel requirements. Regulatory and policy analyses drew on publicly available guidance, approval summaries, and payer frameworks to ensure alignment with current rules and reimbursement practices.

Clinical evidence synthesis incorporated randomized controlled trials, meta-analyses, and key real-world studies to characterize therapeutic profiles and practical considerations around titration and adherence. Supply-chain assessments employed supplier mapping, inspection records, and logistics performance indicators to identify common resilience strategies and potential bottlenecks. Commercial and distribution insights were triangulated through interviews, distributor capability evaluations, and public tender documentation where available to provide a holistic understanding of channel dynamics.

Throughout the methodology, data integrity and transparency were prioritized: sources are cited in the main report, potential biases from respondent samples are disclosed, and sensitivity analyses were used where appropriate to test qualitative conclusions. This methodological framework supports robust, actionable insights without relying on speculative numeric projections.

Concise synthesis highlighting the interconnected priorities of clinical credibility, operational resilience, and payer collaboration required for sustained access and adoption

In sum, sacubitril valsartan sodium remains central to heart failure care, yet its commercial and operational context is evolving rapidly due to evidence generation, regulatory refinement, distribution innovation, and policy-driven supply challenges. Organizations that integrate clinical evidence strategies with diversified manufacturing footprints and channel-specific commercial models will be best positioned to maintain access and preserve value in complex procurement environments.

Strategic investments in real-world outcomes, supply-chain redundancy, and payer-engagement capabilities are practical levers for maintaining prescribing momentum and managing cost pressures. Moreover, aligning regulatory strategy with post-market surveillance and clinician education mitigates adoption barriers while supporting long-term formulary inclusion. By focusing on these interconnected priorities-clinical credibility, operational resilience, and payer collaboration-manufacturers and distributors can build durable programs that respond to both clinical needs and policy variability.

The conclusion underscores an imperative for proactive planning and cross-functional coordination: clinical affairs, supply chain, regulatory, and commercial teams must work in concert to translate evidence into access and to secure resilience against trade and logistical disruptions that can otherwise interrupt patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Sacubitril Valsartan Sodium Drugs Market, by Type

  • 8.1. Brand
  • 8.2. Generic

9. Sacubitril Valsartan Sodium Drugs Market, by Strength

  • 9.1. 24 26 Mg
  • 9.2. 49 51 Mg
  • 9.3. 97 103 Mg

10. Sacubitril Valsartan Sodium Drugs Market, by End User

  • 10.1. Clinics
  • 10.2. Home Care
  • 10.3. Hospitals

11. Sacubitril Valsartan Sodium Drugs Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Sacubitril Valsartan Sodium Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Sacubitril Valsartan Sodium Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Sacubitril Valsartan Sodium Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Sacubitril Valsartan Sodium Drugs Market

16. China Sacubitril Valsartan Sodium Drugs Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Aspen Pharmacare Holdings Limited
  • 17.6. Aurobindo Pharma Limited
  • 17.7. Cipla Limited
  • 17.8. Dr. Reddy's Laboratories Ltd.
  • 17.9. Glenmark Pharmaceuticals Ltd.
  • 17.10. Hetero Labs Limited
  • 17.11. Lupin Limited
  • 17.12. MacLeod's Pharmaceuticals Ltd.
  • 17.13. MSN Laboratories Private Limited
  • 17.14. Mylan N.V.
  • 17.15. Natco Pharma Limited
  • 17.16. Novartis AG
  • 17.17. Orion Corporation
  • 17.18. Pfizer Inc.
  • 17.19. Sandoz International GmbH
  • 17.20. Sun Pharmaceutical Industries Ltd.
  • 17.21. Teva Pharmaceutical Industries Ltd.
  • 17.22. Torrent Pharmaceuticals Ltd.
  • 17.23. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY BRAND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY BRAND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY BRAND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY 24 26 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY 24 26 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY 24 26 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY 49 51 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY 49 51 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY 49 51 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY 97 103 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY 97 103 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY 97 103 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 38. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 39. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 40. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 42. NORTH AMERICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 44. NORTH AMERICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. LATIN AMERICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. LATIN AMERICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. LATIN AMERICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. MIDDLE EAST SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. MIDDLE EAST SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. MIDDLE EAST SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 65. MIDDLE EAST SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. MIDDLE EAST SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. AFRICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. AFRICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AFRICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 70. AFRICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. AFRICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. ASEAN SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. ASEAN SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. ASEAN SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 81. ASEAN SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. ASEAN SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. GCC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GCC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. GCC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 86. GCC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. GCC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPEAN UNION SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPEAN UNION SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPEAN UNION SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPEAN UNION SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPEAN UNION SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. BRICS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. BRICS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. BRICS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 96. BRICS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. BRICS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. G7 SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. G7 SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. G7 SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 101. G7 SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. G7 SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. NATO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NATO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NATO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 106. NATO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. NATO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 110. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 112. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. CHINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. CHINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. CHINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 117. CHINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. CHINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)